Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress

Michelle T. Lee, Dhruv Mahtta, Louis Dlouhy, Hunaina Shahab, Mahmoud Al Rifai, Salim S. Virani

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)


Purpose of Review: This review highlights select studies presented at the virtual 2021 European Society of Cardiology (ESC) Congress. Recent Findings: Reviewed studies assess single photon emission computed tomography, positron emission tomography, magnetic resonance imaging in coronary artery disease (PACIFIC-II); empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); dapagliflozin in chronic heart failure (DAPA-HF); proprotein convertase subtilisin/kexin type 9 inhibitor and its lipid lowering effects (NATURE-PCSK9); fixed-dose combination therapies with or without aspirin in primary prevention; overview of contrasting results between REDUCE-IT versus STRENGTH trials; Quadruple UltrA-low-dose tReaTment for hypertension (QUARTET); evolocumab and changes in plaque composition on optical coherence tomography (HUYGENS); and low-dose rivaroxaban during the acute phase of acute coronary syndrome (H-REPLACE). Summary: Research presented at the 2021 ESC Congress shows promise in reducing burden of cardiovascular disease and reinforces the value of cardiovascular disease prevention.

Original languageEnglish
Article number76
JournalCurrent Atherosclerosis Reports
Issue number12
Publication statusPublished - Dec 2021
Externally publishedYes


  • Aspirin
  • Atherosclerotic cardiovascular disease
  • Cardiovascular prevention
  • Dapagliflozin
  • Empagliflozin
  • Heart failure


Dive into the research topics of 'Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress'. Together they form a unique fingerprint.

Cite this